Clinical Research Directory

Inclusion Criteria: * Cisgender women assigned female at birth * Age 18 years or older * Stage 1-3 hormone receptor-positive breast cancer 1. Premenopausal patients being treated with GNRH agonist/antagonist to induce menopause are eligible 2. Patients who received treatment with CDK 4/6 inhibitors are eligible * Recommended to continue AET for ≥2 additional years after enrollment * Low adherence defined as prescription fills with a proportion of days covered (PDC) of \<80%, examined over all fills during the 2 years prior to date of eligibility review since the first AET prescription/data of AET start OR unable to calculate adherence * Verbal fluency in English or Spanish * Ability to understand informed consent and the willingness to sign it Exclusion Criteria: * Unable to verbalize comprehension of study or impaired decision-making * Known distant metastatic disease * Not receiving breast cancer care or AET prescription from provider at participating site * Evidence that an oncology provider discontinued their AET * Pregnant or trying to get pregnant * Facility-administered medications (i.e., nursing home, home healthcare agency)